Vectans Pharma

Vectans Pharma is a European-based pharmaceutical company primarily focused on the acquisition and global commercial development of innovative targeted therapies in the field of oral pathology.Founded in 2015 by Jean and Jérôme Théron, Vectans Pharma receives strategic and financial support from top-tier private investors in the healthcare industry.Their current portfolio includes two products approved by the EMA (European Medicines Agency) and FDA (Food and Drug Administration), as well as one proprietary innovative galenic technology: Lauriad, Sitavig®, and Loramyc®. Specifically for the U.S., Vectans Pharma holds marketing authorization in most European markets. International expansion will continue across Asia and Europe.To distribute Sitavig® and Loramyc® products, Vectans has signed nine international licensing agreements in Europe, the U.S., and Asia.Vectans Pharma is committed to rapidly becoming a globally leading pharmaceutical company in oral pathology, providing support for patients with unmet medical needs.